First-in-class approval and proof of concept [2]
Approved in 2005, exenatide established that GLP-1 receptor agonism was a viable therapeutic strategy in type 2 diabetes. Every agent documented on this site descends from that result.
PrecisePep/Peptide Library/Exenatide
Metabolic & Adipose Regulation
Exenatide
Byetta® · Bydureon® · exendin-4 · AC2993
The first GLP-1 agonist ever approved, and not a human peptide at all — it comes from the venom of a lizard, and it is the reason this entire drug class exists.
00 Overview
This drug class exists because of a lizard. Exendin-4 was isolated from the venom of the Gila monster, a desert lizard that eats a few times a year and needs to manage enormous, infrequent glucose loads. The peptide turned out to be a potent GLP-1 receptor agonist that — unlike human GLP-1 — resists degradation by DPP-IV. Exenatide is a synthetic version of it, approved in 2005 as the first GLP-1 agonist available anywhere.
It is only about 53% homologous to human GLP-1, the lowest in the class, which is both why it survives in circulation and why it is the most immunogenic member — anti-drug antibodies are considerably more common than with the human-analogue agents.
It has been comprehensively superseded. HbA1c reduction and weight loss both sit below semaglutide and far below tirzepatide, gastrointestinal adverse effects were prominent, and its cardiovascular outcomes trial (EXSCEL) did not demonstrate superiority.[1] Commercial availability has been progressively withdrawn. It remains historically important, and it retains a real body of PCOS trial evidence that later agents are still borrowing from.
Renal clearance sets it apart
Every other agent in this class is cleared by proteolysis and can be used across most degrees of renal impairment. Exenatide is renally cleared and is contraindicated in severe impairment (eGFR below 30), with caution below 45. In a diabetes population — where chronic kidney disease is common and frequently undiagnosed — that is the most clinically important difference on this page.
// Mechanism of action
GLP-1 receptor agonism. The standard class mechanism: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite suppression.
DPP-IV resistance by sequence, not modification. Where semaglutide and liraglutide are engineered human analogues with fatty-acid chains, exendin-4 is naturally resistant because it is a different molecule from a different species. No acylation is needed.
Pronounced gastric emptying effect. Twice-daily exenatide produces a stronger postprandial gastric-emptying effect than the long-acting agents, which is why it lowers post-meal glucose excursions effectively while doing less for fasting glucose.
Renal elimination. Cleared by glomerular filtration and proteolytic degradation in the kidney — the property that produces the renal contraindication and distinguishes it pharmacokinetically from the rest of the class.
Immunogenicity. Low homology to human GLP-1 means anti-exenatide antibodies form in a substantial proportion of users. High titres have been associated with attenuated glycaemic response.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Effective postprandial glucose control [2]
The twice-daily formulation is particularly effective at blunting post-meal glucose excursions, reflecting its pronounced gastric-emptying effect.
Cardiovascular safety, not superiority (EXSCEL) [1]
The once-weekly formulation was evaluated in over 14,000 participants and met non-inferiority for cardiovascular safety but did not demonstrate superiority — unlike LEADER, REWIND and SELECT for other agents in the class.
Substantial randomised PCOS evidence [3]
Alongside liraglutide, exenatide accounts for much of the randomised PCOS data in this class, including comparisons and combinations with metformin reporting improved insulin sensitivity, weight and menstrual regularity.
Weaker efficacy than modern agents [2]
HbA1c reduction and weight loss both sit clearly below semaglutide and tirzepatide in head-to-head and indirect comparison. This is the reason it was superseded, and it is a finding rather than a marketing position.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Useful where postprandial excursions dominate
The twice-daily formulation targets post-meal glucose more specifically than long-acting agents. A coherent clinical niche, largely irrelevant now that the drug is being withdrawn.
Neuroprotection in Parkinson disease [4]
Exenatide generated genuine interest in Parkinson disease, with a positive phase 2 signal followed by a larger trial that did not confirm it. A cautionary example of an encouraging early result not replicating.
Historical value as a comparator
Much of the comparative literature for newer agents used exenatide as the active control, so understanding it is useful for reading those trials.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Prominent nausea
Consistently reported as worse than the modern agents, particularly with the twice-daily formulation.
Injection-site nodules with the weekly formulation
Bydureon uses a microsphere delivery system, and palpable injection-site nodules are a well-recognised and frequently reported consequence.
Rarely sought now
Community interest is minimal — the newer agents outperform it on every axis people care about.
Occasionally encountered as a legacy prescription
Some long-term patients remain on it and report stable control, which is a reasonable outcome for a drug that works, just less well than what followed.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Gastrointestinal adverse events — prominent [2]
Nausea and vomiting at rates generally higher than the modern agents, particularly with twice-daily dosing.
Contraindicated in severe renal impairment [5]
Renal clearance means exenatide is contraindicated at eGFR below 30 and used with caution below 45. Unique among the commonly used agents in this class and clinically significant in a diabetes population.
Acute kidney injury and worsening renal function [5]
Post-marketing reports, some in patients with pre-existing renal impairment or on concurrent nephrotoxic drugs. A labelled warning.
Pancreatitis [5]
A labelled class warning, with exenatide featuring prominently in the early post-marketing signal that established the concern.
Boxed warning on the weekly formulation [5]
Bydureon carries a boxed warning for thyroid C-cell tumours from rodent findings, with contraindication in medullary thyroid carcinoma and MEN2. The twice-daily Byetta formulation does not carry this warning.
Immunogenicity [2]
Anti-exenatide antibodies form in a substantial proportion of users, and high titres have been associated with reduced glycaemic response.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Hypoglycaemia with insulin or sulfonylureas
As across the class — glucose-dependence does not protect against concurrent insulin or sulfonylurea therapy.
Renal function should be known before use
The one contraindication genuinely specific to this agent, in a population where chronic kidney disease is common and frequently undiagnosed.
Altered levothyroxine absorption
Delayed gastric emptying alters absorption of a narrow-therapeutic-index, fasting-dependent drug — arguably more pronounced with the twice-daily formulation.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Nausea, frequently limiting
The dominant complaint and a common reason for discontinuation.
Injection-site nodules
Characteristic of the weekly microsphere formulation, sometimes persisting for weeks.
Reconstitution difficulty with the weekly product
The original Bydureon kit required a mixing procedure widely described as fiddly — later autoinjector versions addressed this.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Byetta: 5 mcg twice daily, increased to 10 mcg [5]
5 mcg twice daily within 60 minutes before morning and evening meals for one month, then 10 mcg twice daily if tolerated. Meal-timed rather than fixed-schedule, unlike the rest of the class.
Bydureon: 2 mg once weekly [5]
A fixed weekly dose with no titration — the extended-release microsphere formulation.
| Product | Dose | Frequency | Timing |
|---|---|---|---|
| Byetta | 5 mcg → 10 mcg | Twice daily | Within 60 min before meals |
| Bydureon | 2 mg | Once weekly | Any time, no titration |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The meal-timing requirement is a real adherence burden
Twice-daily pre-meal dosing is considerably more demanding than a weekly injection, and is part of why the class moved away from it.
Check renal function first
The one agent in this class where that is a specific requirement rather than general good practice.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Rarely used in community settings
The grey market has largely moved past it, and there is little contemporary community dosing discussion to document.
Legacy prescription use at labelled doses
Where it is encountered, it is usually a long-standing prescription being taken as labelled.
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Studied with metformin, sulfonylureas and insulin glargine [2]
A substantial combination trial literature, including the comparisons against liraglutide and dulaglutide that helped establish the modern hierarchy.
Exenatide plus metformin in PCOS [3]
Randomised work has compared and combined exenatide with metformin in PCOS, reporting improvements in insulin sensitivity, weight and menstrual regularity — part of the evidence base later agents borrow from.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Do not combine with another GLP-1 agonist
Same receptor, additive adverse effects, no additional mechanism.
Serious interaction: insulin and sulfonylureas
Requires dose reduction of the concurrent agent.
Oral drug absorption [5]
The pronounced gastric-emptying effect makes this a more significant consideration than with the long-acting agents. The label advises separating oral medications requiring rapid absorption.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Alongside metformin
The standard clinical pairing where it is still used.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Renal function before starting, and monitored during
The agent-specific requirement that distinguishes this from the rest of the class.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Little contemporary community practice
Superseded commercially and in community use alike.
05b Condition-specific interest
Exenatide is the oldest agent in its class and it is now most interesting for something that has nothing to do with diabetes: it produced the clearest cautionary tale in modern neurology trials, and the result was published in 2025.
No approval, no trial
Approved for type 2 diabetes. Everything else on this page is investigational or off-label. Uniquely in its class, exenatide is contraindicated below an eGFR of 30 — which matters because renal impairment is common in the population it treats.
Study — randomised, small, and the more encouraging of the two
Smoking cessation — the trial that was positive
Pathophysiology
Nicotine dependence is maintained through mesolimbic dopamine signalling, and post-cessation weight gain is a documented barrier to quitting.
Mechanistic rationale
Extended-release exenatide 2 mg weekly for six weeks was given alongside a 21 mg nicotine patch and behavioural counselling. Abstinence was 46.3% against 26.8% on patch alone, with reduced craving and withdrawal symptoms. That is a substantially better result than the dulaglutide trial produced on the same endpoint, in a smaller study with a different background treatment.
Community reports
Two randomised trials, two different answers on abstinence, roughly 410 participants across the whole randomised literature including a third study. That is not an established treatment; it is an open question with a promising signal — and in both trials the GLP-1 was added to something that already works.
Components carrying the argument: GLP-1 receptor — nicotine reward signalling
Study — randomised, definitive, negative
Parkinson disease — the phase 3 that said no
Pathophysiology
Parkinson disease involves progressive loss of dopaminergic neurones. Nothing in routine use slows that progression — every approved treatment is symptomatic, which is why a disease-modifying candidate attracts enormous attention.
Mechanistic rationale
Epidemiology linked GLP-1 agonist use to lower Parkinson incidence, laboratory work supported neuroprotection, and a phase 2 trial reported encouraging results. Exenatide-PD3 — 194 participants, 96 weeks, randomised, double-blind, placebo-controlled — found no benefit over placebo and no slowing of progression, published in The Lancet in February 2025. The authors noted the result was discordant with the earlier laboratory, epidemiological and phase 2 findings.
Community reports
GLP-1 agonists are still discussed for neuroprotection, frequently citing the phase 2 result. This is the single best example in the library of why phase 2 enthusiasm is not evidence — the properly powered trial was run, and it answered the question.
Components carrying the argument: GLP-1 receptor — the neuroprotection hypothesis, tested
Study — approved
Type 2 diabetes — the approved indication
Pathophysiology
Insulin resistance with progressive beta-cell failure.
Mechanistic rationale
Exendin-4, isolated from Gila monster venom, was the first GLP-1 agonist approved and established the class. Twice-daily and weekly formulations exist. It has been superseded on efficacy by semaglutide and tirzepatide, and its cardiovascular outcome trial did not demonstrate superiority in the way SUSTAIN-6 and LEADER did.
Community reports
Little grey-market presence — the newer agents dominate on effect size and dosing convenience.
Components carrying the argument: GLP-1 receptor agonism
Actionable — unique in the class
The renal contraindication
Pathophysiology
Exenatide is cleared renally, unlike the acylated and Fc-fused analogues that are degraded proteolytically.
Mechanistic rationale
It is contraindicated below eGFR 30 and requires caution between 30 and 50. That is a genuine class outlier: semaglutide has renal outcome data and is used in chronic kidney disease, while this agent is withheld in it. Anyone comparing GLP-1 agonists on renal grounds should know they behave oppositely here.
Community reports
Not widely known. Acute kidney injury and worsening renal function are labelled concerns.
Components carrying the argument: Renal clearance
Theorized — the class has the data, this agent does not
Obesity, PCOS and the class extrapolations
Pathophysiology
Weight and insulin resistance drive much of the metabolic and reproductive burden in both.
Mechanistic rationale
The class effects apply, and the trials were run with other agents. Exenatide holds no obesity indication, and where randomised PCOS evidence exists in this class it is largely liraglutide and semaglutide. There is no reason to choose this agent for either.
Community reports
Rarely used for weight, appropriately.
Components carrying the argument: Class effect, weakest member
| Question | Position |
|---|---|
| Approved for | Type 2 diabetes only |
| Parkinson disease | Phase 3 negative — Lancet, Feb 2025, 194 participants |
| Why that matters | Phase 2 and epidemiology both pointed the other way |
| Renal | Contraindicated below eGFR 30 — unique in the class |
| Obesity | No indication |
| Origin | Exendin-4, from Gila monster venom |
What actually has evidence for these conditions
For type 2 diabetes: metformin first, SGLT2 inhibitors and GLP-1 agonists with cardiovascular and renal outcome data, structured education, and exercise and dietary change that alter the trajectory of the disease.
For Parkinson disease: levodopa remains the most effective symptomatic treatment, with dopamine agonists, MAO-B inhibitors and deep brain stimulation in selected patients. Exercise has among the best evidence of any non-pharmacological intervention and is under-prescribed. No disease-modifying therapy exists, and the exenatide result is part of why that sentence is still true.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Byetta ships as a ready-to-use pen. Bydureon requires reconstitution of a microsphere suspension in its original kit form, a procedure widely described as difficult; later autoinjector presentations simplified it. Research-grade exenatide is uncommon and rarely sought.
Storage
Refrigerated 2–8 °C, with defined in-use periods. Protect from light. Do not freeze.
Common vial sizes
Licensed: Byetta 5 and 10 mcg pens; Bydureon 2 mg weekly presentations.
Stability notes
Commercial availability has been progressively withdrawn in several markets, so supply is increasingly a limiting factor regardless of handling.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Approved, but being withdrawn. Exenatide was licensed as Byetta (2005) and Bydureon (extended release). Commercial availability has been progressively discontinued in multiple markets as the class moved on — a business decision rather than a safety withdrawal.
The weekly formulation carries a boxed warning for thyroid C-cell tumours; the twice-daily formulation does not. Both are contraindicated in severe renal impairment.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: Exenatide-PD3 phase 3 negative result (Lancet, Feb 2025); the exenatide smoking cessation RCT. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
Metabolic modulators and peptide hormones are addressed under the WADA Prohibited List. Verify against the current list.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL). N Engl J Med. 2017;377(13):1228–1239.Registered clinical trial
- PubMed: exenatide / exendin-4 — clinical trials in type 2 diabetes (live query)Database or literature search
- PubMed: exenatide in polycystic ovary syndrome, including comparisons with metformin (live query)Database or literature search
- PubMed: exenatide in Parkinson disease — phase 2 and subsequent trials (live query)Database or literature search
- FDA Drugs@FDA — Byetta and Bydureon prescribing information, renal contraindicationRegulatory / official document
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.